Literature DB >> 15665617

Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?

Shota Konishi1, Klaus Hamacher, Shankar Vallabhajosula, Paresh Kothari, Diago Bastidas, Neil Bander, Stanley Goldsmith.   

Abstract

Determination of the immunoreactive fraction (IF) of radiolabeled monoclonal antibodies (MAb) is essential to the understanding of the effects of radiolabeling and subsequent target-specific tumor localization. There has been generally no accepted method of determining the IF of MAbs. The conventional method is based on a radioimmunoassay technique in which the fraction of radiolabeled MAb bound to antigen under conditions of "antigen excess" is determined. Lindmo et al. introduced a modified method in which the IF is determined by extrapolation to conditions representing "infinite antigen excess." Although the Lindmo method, in principle, is insensitive to experimental parameters, it does not always provide a reliable estimate of IF. We, therefore, evaluated an alternate method in which percent cell bound fraction is measured under conditions of fixed antigen concentration and various dilutions of radiolabeled MAb. We developed a mathematical equation to estimate immunoreactivity. J591 MAb specific for prostate-specific membrane antigen was radiolabeled with (111)In, (90)Y and (177)Lu to specific activities of 1-20 mCi/mg. We compared the effect of several experimental conditions on the determination of IF using all three different methods. The Lindmo method requires careful optimization of experimental conditions for each radiolabeled MAb. The alternate method, based on a fixed antigen concentration, appears to be practical and may provide a more reliable measure of immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15665617     DOI: 10.1089/cbr.2004.19.706

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  9 in total

1.  Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.

Authors:  Mohanambe Lingappa; Hong Song; Sarah Thompson; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2010-07-22       Impact factor: 12.701

2.  Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.

Authors:  Sangeeta Ray Banerjee; Vivek Kumar; Ala Lisok; Donika Plyku; Zora Nováková; Mary Brummet; Bryan Wharram; Cyril Barinka; Robert Hobbs; Martin G Pomper
Journal:  J Nucl Med       Date:  2018-09-20       Impact factor: 10.057

3.  Light-Induced Radiosynthesis of 89Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor.

Authors:  Simon Klingler; Rachael Fay; Jason P Holland
Journal:  J Nucl Med       Date:  2020-01-10       Impact factor: 10.057

Review 4.  Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with 90Y or 177Lu.

Authors:  Urszula Karczmarczyk; Agnieszka Sawicka; Piotr Garnuszek; Michał Maurin; Wioletta Wojdowska
Journal:  J Med Chem       Date:  2022-04-20       Impact factor: 8.039

Review 5.  Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy.

Authors:  Tyler G St Denis; Michael R Hamblin
Journal:  Bioanalysis       Date:  2013-05       Impact factor: 2.681

6.  Simultaneous Photoradiochemical Labeling of Antibodies for Immuno-Positron Emission Tomography.

Authors:  Malay Patra; Simon Klingler; Larissa S Eichenberger; Jason P Holland
Journal:  iScience       Date:  2019-03-07

7.  A Robust Method for Assaying the Immunoreactive Fraction in Nonequilibrium Systems.

Authors:  Thibaut Denoël; Luca Pedrelli; Giuseppe Pantaleo; John O Prior
Journal:  Pharmaceuticals (Basel)       Date:  2019-12-03

8.  Supramolecular Rotaxane-Based Multi-Modal Probes for Cancer Biomarker Imaging.

Authors:  Faustine d'Orchymont; Jason P Holland
Journal:  Angew Chem Int Ed Engl       Date:  2022-05-20       Impact factor: 16.823

9.  A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.

Authors:  Babak Behnam Azad; Samit Chatterjee; Wojciech G Lesniak; Ala Lisok; Mrudula Pullambhatla; Zaver M Bhujwalla; Martin G Pomper; Sridhar Nimmagadda
Journal:  Oncotarget       Date:  2016-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.